Sign in
Not yet recruitingPhase 1

Testing YG-01 for safety and dose in people with glioblastoma

Tests a new drug, YG-01, in adults with glioblastoma, a brain tumor.

Key facts

Who runs it
YGION Biomedical GmbH
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
Status
Not yet recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
Nov 2026
Expected to end
Nov 2029
Type of study
Interventional, 2 groups
Treatments tested
  • YG-01 Dose Level 1
  • YG-01 Dose Level 2
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Other criteria

  • Pre-Production Screening inclusion criteria:
  • Patient provided written informed consent for study participation prior to initiation of any study specific activities/procedures
  • Histologically confirmed glioblastoma, IDH wild type, WHO CNS Grade 4 - classification according to WHO classification of CNS tumors 2021; patients of dose escalation cohorts are required to have undergone extensive tumor resection documented by post-surgical magnetic resonance imaging (MRI) demonstrating either no contrast enhancement or no greater than 1 cm x 1 cm x 1 cm volume of residual enhancing tumor
  • Age ≥18 years
  • ECOG 0-1
  • At least 4 manufacturable neoepitopes identified in a preceding tumor sample analysis study and availability of a manufacturing slot confirmed by the sponsor
  • Stable disease or no measurable disease according to local investigator assessment, following at least two MRI scans taken a minimum of 8 weeks apart, both conducted after the completion of standard 6 weeks radiotherapy with concurrent temozolomide; Pre-Therapy Screening inclusion criteria:
  • Having completed maintenance temozolomide therapy, received at least 4 cycles of temozolomide, and having an interval of at least 4 weeks between the last dose of temozolomide and the first administration of study medication
  • Stable disease or no measurable disease according to local investigator assessment, following an MRI scan taken after the completion of maintenance temozolomide therapy
  • Life expectancy > 3 months at start of study treatment as clinically determined by the investigator
  • ECOG 0-1
  • Availability of study medication confirmed by the sponsor
  • Absolute lymphocyte count (ALC) >0.75 x10\^9/L
  • No need for dexamethasone or any other steroid treatment within 1 week prior to baseline
  • No need for bevacizumab treatment within 1 week prior to baseline; Pre-Production Screening exclusion criteria:
  • Known HIV or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Immunosuppression, not related to treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding; Pre-Therapy Screening exclusion criteria:
  • Abnormal (≥ grade 2 CTCAE v6.0) laboratory values for hematology, liver and renal function (serum creatinine)
  • HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Any vaccination within 2 weeks prior to baseline
  • Immunosuppression, not related to prior treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • How old are you?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.

The 2 groups in the trial

  • Dose Level 1Treatment being tested

    Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.

    Treatment: YG-01 Dose Level 1

  • Dose Level 2Treatment being tested

    Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.

    Treatment: YG-01 Dose Level 2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma
Plain-language title
Testing YG-01 for safety and dose in people with glioblastomaGenerated from the registry record. The registry title is the official one.
Fit questions
Built from NCT07930338, who can take part
Record updated
12 November 2026